

HMMR Antibody (C-term)

Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP11771b

Specification

HMMR Antibody (C-term) - Product Information

Application
Primary Accession
Other Accession
Reactivity
Host
Clonality
Isotype
Antigen Region

WB, IHC-P, FC,E
075330
NP_036616.2
Human, Mouse
Rabbit
Polyclonal
Rabbit IgG
668-697

HMMR Antibody (C-term) - Additional Information

Gene ID 3161

Other Names

Hyaluronan mediated motility receptor, Intracellular hyaluronic acid-binding protein, Receptor for hyaluronan-mediated motility, CD168, HMMR, IHABP, RHAMM

Target/Specificity

This HMMR antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 668-697 amino acids from the C-terminal region of human HMMR.

Dilution

WB~~1:2000 IHC-P~~1:50~100 FC~~1:10~50

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

HMMR Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

HMMR Antibody (C-term) - Protein Information

Name HMMR



Synonyms IHABP, RHAMM

Function Receptor for hyaluronic acid (HA) (By similarity). Involved in cell motility (By similarity). When hyaluronan binds to HMMR, the phosphorylation of a number of proteins, including PTK2/FAK1 occurs. May also be involved in cellular transformation and metastasis formation, and in regulating extracellular-regulated kinase (ERK) activity. May act as a regulator of adipogenisis (By similarity).

Cellular Location

Cell surface {ECO:0000250|UniProtKB:Q00547}. Cytoplasm {ECO:0000250|UniProtKB:Q00547}. Cytoplasm, cytoskeleton, spindle {ECO:0000250|UniProtKB:Q00547}

Tissue Location


Expressed in testis (PubMed:22965910). Expressed in the breast (PubMed:8890751).

HMMR Antibody (C-term) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- <u>Immunoprecipitation</u>
- Flow Cytomety
- Cell Culture

HMMR Antibody (C-term) - Images




HMMR Antibody (C-term) (Cat. #AP11771b) western blot analysis in Ramos cell line lysates (35ug/lane). This demonstrates the HMMR antibody detected the HMMR protein (arrow).







All lanes: Anti-HMMR Antibody (C-term) at 1:2000 dilution Lane 1: K562 whole cell lysates Lane 2: LNCaP whole cell lysates Lane 3: HL-60 whole cell lysates Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution Predicted band size: 84 kDa Blocking/Dilution buffer: 5% NFDM/TBST.



HMMR Antibody (C-term) (Cat. #AP11771b)immunohistochemistry analysis in formalin fixed and paraffin embedded human breast carcinoma followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of HMMR Antibody (C-term) for immunohistochemistry. Clinical relevance has not been evaluated.







Tel: 858.875.1900 Fax: 858.875.1999

HMMR Antibody (C-term) (Cat. #AP11771b) flow cytometric analysis of Ramos cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.

HMMR Antibody (C-term) - Background

The protein encoded by this gene is involved in cell motility. It is expressed in breast tissue and together with other proteins, it forms a complex with BRCA1 and BRCA2, thus is potentially associated with higher risk of breast cancer. Alternatively spliced transcript variants encoding different isoforms have been noted for this gene.

HMMR Antibody (C-term) - References

Huang, T.W., et al. Biomaterials 31(26):6701-6709(2010) Nagel, S., et al. Exp. Hematol. 38(1):38-45(2010) Gust, K.M., et al. Neoplasia 11(9):956-963(2009) Shigeishi, H., et al. Int. J. Oncol. 34(6):1565-1571(2009) Luczynski, W., et al. Neoplasma 56(5):428-434(2009)